Drug-like new molecules predicting non-toxic low-nanoMolar affinities to human hypermutator A3A enzyme models and low cross-docking with other human A3 enzymes, have been computationally predicted. The predicted topchildren targeted either ssDNA-docking or dimer-interface cavities of A3A, an enzyme implicated on many different tumor progressions into metastatic cancers. DWBEL co-evolution and ADV docking predicted two kinds of star-shaped molecular candidates. These new candidates may offer some examples for experimental evaluation of their mutational anti-cancerogenesis. New combinatorial chemical synthesis and/or searching for chemical analogues among recently avialable large modular banks, may help to their chemical synthesis for possible experimental confirmations.